By Nancy LapidMay 1 (Reuters) - We also report on a new use for artificial intelligence that could help eliminate some racial inequities in heart disease diagnoses.MODIFIED
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy LapidApril 29 (Reuters) - We also report b
Patient and expert perspectives
Read a transcript of Christine Pratilas discussing the Johns Hopkins NF1 biorepository, genomic data sharing, and research impact in NF1.
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy LapidMay 8 (Reuters) - We also report on a
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)By Nancy LapidMay 6 (Reuters) - We also report on t
In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study investigators, Dr. Hyo-Soo Kim presented the results of a stent level analysis comparing two ultrathin strut drug-eluting stents (DES): Orsiro and Coroflex ISAR . The post-hoc comparison revealed significant differences in efficacy.
Gilead Sciences, Inc. announced that the FDA approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Eylea HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).